{"title":"α-突触核蛋白包裹酪氨酸羟化酶和多巴胺ß-羟化酶,可能减少多巴胺和去甲肾上腺素的合成。","authors":"Steven Lehrer, Peter H Rheinstein","doi":"10.1007/s42485-022-00088-z","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Parkinson's disease (PD) results from degeneration of dopamine and norepinephrine neurons due to α-synuclein aggregates that likely have their origin in the gut. Tyrosine hydroxylase (TH) catalyses the formation of L-DOPA, the rate-limiting step in the biosynthesis of dopamine. A second enzyme, DOPA decarboxylase (DDC), catalyzes the conversion of L-DOPA to dopamine. A third enzyme, dopamine ß-hydroxylase (DBH), catalyzes the conversion of dopamine to norepinephrine. To analyze possible interactions of α-synuclein with TH, DDC and DBH, we performed in silico protein-protein docking.</p><p><strong>Methods: </strong>Protein data bank (pdb) entries were searched on the RCSB Protein Data Bank. We identified four structures that allowed us to examine the relationship of α-synuclein with TH, DDC, and DBH: (1) Human micelle-bound alpha-synuclein, (2) solution structure of the regulatory domain of tyrosine hydroxylase (<i>Rattus norvegicus</i>), (3) crystal structure of human aromatic L-amino acid decarboxylase (DOPA decarboxylase) in the apo form and (4) crystal structure of human dopamine ß-hydroxylase at 2.9 angstrom resolution. We used the ClusPro server (https://cluspro.org) for protein-protein docking. The protein structures were visualized with PyMOL v 2.3.4.</p><p><strong>Results: </strong>α-synuclein partially enfolds tyrosine hydroxylase and dopamine ß-hydroxylase, potentially reducing dopamine and norepinephrine synthesis. α-synuclein may dock too far away from DOPA decarboxylase to affect its function directly.</p><p><strong>Conclusions: </strong>Our in silico finding of α-synuclein partly enfolding tyrosine hydroxylase and dopamine ß-hydroxylase suggests that α-synuclein docking inhibition could increase dopamine and norepinephrine biosynthesis, ameliorating PD symptoms. Small molecules that bind to α-synuclein have already been identified. Further studies may lead to new small molecule drugs that block α-synuclein enfolding of tyrosine hydroxylase and dopamine ß-hydroxylase.</p>","PeriodicalId":73910,"journal":{"name":"Journal of proteins and proteomics","volume":" ","pages":"109-115"},"PeriodicalIF":0.0000,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585989/pdf/nihms-1809942.pdf","citationCount":"0","resultStr":"{\"title\":\"α-synuclein enfolds tyrosine hydroxylase and dopamine ß-hydroxylase, potentially reducing dopamine and norepinephrine synthesis.\",\"authors\":\"Steven Lehrer, Peter H Rheinstein\",\"doi\":\"10.1007/s42485-022-00088-z\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Parkinson's disease (PD) results from degeneration of dopamine and norepinephrine neurons due to α-synuclein aggregates that likely have their origin in the gut. Tyrosine hydroxylase (TH) catalyses the formation of L-DOPA, the rate-limiting step in the biosynthesis of dopamine. A second enzyme, DOPA decarboxylase (DDC), catalyzes the conversion of L-DOPA to dopamine. A third enzyme, dopamine ß-hydroxylase (DBH), catalyzes the conversion of dopamine to norepinephrine. To analyze possible interactions of α-synuclein with TH, DDC and DBH, we performed in silico protein-protein docking.</p><p><strong>Methods: </strong>Protein data bank (pdb) entries were searched on the RCSB Protein Data Bank. We identified four structures that allowed us to examine the relationship of α-synuclein with TH, DDC, and DBH: (1) Human micelle-bound alpha-synuclein, (2) solution structure of the regulatory domain of tyrosine hydroxylase (<i>Rattus norvegicus</i>), (3) crystal structure of human aromatic L-amino acid decarboxylase (DOPA decarboxylase) in the apo form and (4) crystal structure of human dopamine ß-hydroxylase at 2.9 angstrom resolution. We used the ClusPro server (https://cluspro.org) for protein-protein docking. The protein structures were visualized with PyMOL v 2.3.4.</p><p><strong>Results: </strong>α-synuclein partially enfolds tyrosine hydroxylase and dopamine ß-hydroxylase, potentially reducing dopamine and norepinephrine synthesis. α-synuclein may dock too far away from DOPA decarboxylase to affect its function directly.</p><p><strong>Conclusions: </strong>Our in silico finding of α-synuclein partly enfolding tyrosine hydroxylase and dopamine ß-hydroxylase suggests that α-synuclein docking inhibition could increase dopamine and norepinephrine biosynthesis, ameliorating PD symptoms. Small molecules that bind to α-synuclein have already been identified. Further studies may lead to new small molecule drugs that block α-synuclein enfolding of tyrosine hydroxylase and dopamine ß-hydroxylase.</p>\",\"PeriodicalId\":73910,\"journal\":{\"name\":\"Journal of proteins and proteomics\",\"volume\":\" \",\"pages\":\"109-115\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585989/pdf/nihms-1809942.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of proteins and proteomics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s42485-022-00088-z\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/5/21 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of proteins and proteomics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s42485-022-00088-z","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/5/21 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
背景:帕金森病(PD)是由于α-突触核蛋白聚集导致多巴胺和去甲肾上腺素神经元变性而引起的,α-突触核蛋白聚集可能起源于肠道。酪氨酸羟化酶(TH)催化左旋多巴的形成,这是多巴胺生物合成的限速步骤。第二种酶,多巴脱羧酶(DDC),催化左旋多巴转化为多巴胺。第三种酶,多巴胺ß-羟化酶(DBH),催化多巴胺转化为去甲肾上腺素。为了分析α-synuclein与TH、DDC和DBH可能的相互作用,我们进行了硅蛋白-蛋白对接。方法:在RCSB蛋白质数据库中检索蛋白质数据库(pdb)条目。我们确定了四种结构,使我们能够研究α-突触核蛋白与TH、DDC和DBH的关系:(1)人胶束结合α-突触核蛋白,(2)酪氨酸羟化酶(褐家鼠)调节结构域的溶液结构,(3)人芳香l -氨基酸脱羧酶(DOPA脱羧酶)载子形式的晶体结构,(4)人多巴胺ß-羟化酶在2.9埃分辨率下的晶体结构。我们使用ClusPro服务器(https://cluspro.org)进行蛋白质-蛋白质对接。利用PyMOL v 2.3.4对蛋白结构进行可视化分析。结果:α-突触核蛋白部分包裹酪氨酸羟化酶和多巴胺ß-羟化酶,可能减少多巴胺和去甲肾上腺素的合成。α-突触核蛋白可能与多巴脱羧酶距离过远,直接影响其功能。结论:我们在计算机上发现α-突触核蛋白部分包膜酪氨酸羟化酶和多巴胺ß-羟化酶,提示α-突触核蛋白对接抑制可增加多巴胺和去甲肾上腺素的生物合成,改善PD症状。与α-突触核蛋白结合的小分子已经被发现。进一步的研究可能会导致新的小分子药物阻断α-突触核蛋白包膜酪氨酸羟化酶和多巴胺ß-羟化酶。
α-synuclein enfolds tyrosine hydroxylase and dopamine ß-hydroxylase, potentially reducing dopamine and norepinephrine synthesis.
Background: Parkinson's disease (PD) results from degeneration of dopamine and norepinephrine neurons due to α-synuclein aggregates that likely have their origin in the gut. Tyrosine hydroxylase (TH) catalyses the formation of L-DOPA, the rate-limiting step in the biosynthesis of dopamine. A second enzyme, DOPA decarboxylase (DDC), catalyzes the conversion of L-DOPA to dopamine. A third enzyme, dopamine ß-hydroxylase (DBH), catalyzes the conversion of dopamine to norepinephrine. To analyze possible interactions of α-synuclein with TH, DDC and DBH, we performed in silico protein-protein docking.
Methods: Protein data bank (pdb) entries were searched on the RCSB Protein Data Bank. We identified four structures that allowed us to examine the relationship of α-synuclein with TH, DDC, and DBH: (1) Human micelle-bound alpha-synuclein, (2) solution structure of the regulatory domain of tyrosine hydroxylase (Rattus norvegicus), (3) crystal structure of human aromatic L-amino acid decarboxylase (DOPA decarboxylase) in the apo form and (4) crystal structure of human dopamine ß-hydroxylase at 2.9 angstrom resolution. We used the ClusPro server (https://cluspro.org) for protein-protein docking. The protein structures were visualized with PyMOL v 2.3.4.
Results: α-synuclein partially enfolds tyrosine hydroxylase and dopamine ß-hydroxylase, potentially reducing dopamine and norepinephrine synthesis. α-synuclein may dock too far away from DOPA decarboxylase to affect its function directly.
Conclusions: Our in silico finding of α-synuclein partly enfolding tyrosine hydroxylase and dopamine ß-hydroxylase suggests that α-synuclein docking inhibition could increase dopamine and norepinephrine biosynthesis, ameliorating PD symptoms. Small molecules that bind to α-synuclein have already been identified. Further studies may lead to new small molecule drugs that block α-synuclein enfolding of tyrosine hydroxylase and dopamine ß-hydroxylase.